Risk that Emerade pen will fail to activate and deliver adrenaline in an emergency situation
The HPRA wishes to remind patients and their carers of the Emerade product recall from September 2019. Emerade is a medicine used for the emergency treatment of severe acute allergic reactions (anaphylaxis).
The recall is necessary as some Emerade pens may fail to produce an injection when used, due to failure of the pen to activate and the potential for a blocked needle.
The company, Bausch Health, has informed the HPRA that not all pens impacted by the recall have been returned to pharmacies as requested in September last year.
Anyone who is still in possession of any in-date Emerade pens for their own use or for someone in their care is urged to ensure that their pens are brought back to their pharmacy as soon as possible where they will be replaced with an alternative product.
The recall relates to all in-date batches of:
-
Emerade 150mcg pre-filled pens
-
Emerade 300mcg pre-filled pens
-
Emerade 500mcg pre-filled pens
The recall also applies to any Emerade pens that may be stored in other locations, such as schools and childcare facilities.
In line with existing medical guidelines, it is advised that patients continue to carry two pens at all times.
Further Information